Science crosses borders, but do pharma companies when searching for CEOs?

global_stock_large-1-

A widely-coined phrase is that science knows no borders: the effectiveness of medicines depends on a person’s biology rather than their geographic location or their cultural or linguistic ties; a compound does not care about the nationality of the person that discovered it; and an infectious disease pays no heed to lines on maps and political regimes.

So why should pharma, an industry so rooted in science, care about the origins of those finding and developing medicines, and those leading these teams? Surely all that matters is their ability to deliver the most effective and safe drugs to patients as expeditiously as possible? After all, the only issue that matters to a suffering patient is a drug’s ability to provide relief, improve quality of life or extend survival, not the nationality of the manufacturer’s chief executive.

But when viewed from another perspective, it is possible to see why pharma companies have not always ignored the issue of nationality when choosing their leaders.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical